Eugenie S. Kleinerman, holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.Richard Gorlick, is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

• Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma:  A Historical Perspective.- Part 1:  Surgical Considerations and Outcomes.- Limb Salvage and Reconstruction Options in Osteosarcoma.- Advances in the functional assessment of patients with sarcoma.- Part II:  Novel Therapeutic Approaches Based on Biology.- Radiopharmaceuticals for Treatment of Osteosarcoma.- HER-2 Targeted Therapy in Osteosarcoma.- Aerosolized Chemotherapy for Osteosarcoma.- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma.- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease.- Using liquid biopsy in the treatment of patient with osteosarcoma.- Part III:  Novel Immunotherapeutic Approaches.- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020’s.- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.- Natural Killer Cell Immunotherapy for Osteosarcoma.- Nanocapsule delivery of IL-12.- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy.- Part IV:  Survivorship and Late Effects.- Editorial Comments on late effects.- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention.- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors.- Index.

Eugenie S. Kleinerman, holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.Richard Gorlick, is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

• Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma:  A Historical Perspective.- Part 1:  Surgical Considerations and Outcomes.- Limb Salvage and Reconstruction Options in Osteosarcoma.- Advances in the functional assessment of patients with sarcoma.- Part II:  Novel Therapeutic Approaches Based on Biology.- Radiopharmaceuticals for Treatment of Osteosarcoma.- HER-2 Targeted Therapy in Osteosarcoma.- Aerosolized Chemotherapy for Osteosarcoma.- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma.- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease.- Using liquid biopsy in the treatment of patient with osteosarcoma.- Part III:  Novel Immunotherapeutic Approaches.- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020’s.- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.- Natural Killer Cell Immunotherapy for Osteosarcoma.- Nanocapsule delivery of IL-12.- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy.- Part IV:  Survivorship and Late Effects.- Editorial Comments on late effects.- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention.- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors.- Index.

Eugenie S. Kleinerman, holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.Richard Gorlick, is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

• Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma:  A Historical Perspective.- Part 1:  Surgical Considerations and Outcomes.- Limb Salvage and Reconstruction Options in Osteosarcoma.- Advances in the functional assessment of patients with sarcoma.- Part II:  Novel Therapeutic Approaches Based on Biology.- Radiopharmaceuticals for Treatment of Osteosarcoma.- HER-2 Targeted Therapy in Osteosarcoma.- Aerosolized Chemotherapy for Osteosarcoma.- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma.- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease.- Using liquid biopsy in the treatment of patient with osteosarcoma.- Part III:  Novel Immunotherapeutic Approaches.- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020’s.- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.- Natural Killer Cell Immunotherapy for Osteosarcoma.- Nanocapsule delivery of IL-12.- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy.- Part IV:  Survivorship and Late Effects.- Editorial Comments on late effects.- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention.- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors.- Index.